Stock Traders Purchase High Volume of Novo Nordisk A/S Call Options (NYSE:NVO)

Novo Nordisk A/S (NYSE:NVO) was the target of some unusual options trading activity on Friday. Stock investors bought 100,752 call options on the company. This is an increase of approximately 58% compared to the average volume of 63,882 call options.

Analyst Ratings Changes

Several research analysts have recently weighed in on NVO shares. HSBC reissued a “hold” rating on shares of Novo Nordisk A/S in a research report on Monday, July 6th. Wall Street Zen lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Saturday, June 20th. Zacks Research raised Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 11th. Berenberg Bank set a $47.00 target price on Novo Nordisk A/S in a report on Wednesday. Finally, Weiss Ratings raised Novo Nordisk A/S from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, August 5th. Four equities research analysts have rated the stock with a Buy rating and sixteen have issued a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $64.94.

Hedge Funds Weigh In On Novo Nordisk A/S

A number of institutional investors have recently modified their holdings of NVO. Revolve Wealth Partners LLC raised its holdings in Novo Nordisk A/S by 8.7% during the fourth quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock worth $214,000 after buying an additional 200 shares during the last quarter. AQR Capital Management LLC increased its position in shares of Novo Nordisk A/S by 21.0% during the first quarter. AQR Capital Management LLC now owns 62,099 shares of the company’s stock worth $4,312,000 after acquiring an additional 10,758 shares in the last quarter. Sivia Capital Partners LLC increased its position in shares of Novo Nordisk A/S by 18.2% during the second quarter. Sivia Capital Partners LLC now owns 10,320 shares of the company’s stock worth $712,000 after acquiring an additional 1,587 shares in the last quarter. Invesco Ltd. raised its holdings in shares of Novo Nordisk A/S by 26.3% in the 2nd quarter. Invesco Ltd. now owns 419,691 shares of the company’s stock worth $28,967,000 after acquiring an additional 87,467 shares during the last quarter. Finally, Gamco Investors INC. ET AL acquired a new stake in shares of Novo Nordisk A/S in the 2nd quarter worth about $314,000. 11.54% of the stock is owned by institutional investors and hedge funds.

Novo Nordisk A/S Stock Down 1.7%

NYSE:NVO traded down $0.81 during trading hours on Friday, reaching $45.91. The company had a trading volume of 10,833,924 shares, compared to its average volume of 12,845,990. Novo Nordisk A/S has a twelve month low of $35.12 and a twelve month high of $64.16. The company has a quick ratio of 0.56, a current ratio of 0.79 and a debt-to-equity ratio of 0.59. The firm has a market cap of $204.99 billion, a price-to-earnings ratio of 11.23, a P/E/G ratio of 4.15 and a beta of 0.76. The business’s 50-day simple moving average is $47.36 and its two-hundred day simple moving average is $44.51.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings data on Tuesday, June 30th. The company reported $0.94 earnings per share (EPS) for the quarter. Novo Nordisk A/S had a net margin of 35.36% and a return on equity of 61.20%. The company had revenue of $11.98 billion for the quarter. On average, equities analysts expect that Novo Nordisk A/S will post 3.41 earnings per share for the current year.

Novo Nordisk A/S Cuts Dividend

The company also recently disclosed a dividend, which will be paid on Tuesday, August 25th. Shareholders of record on Monday, August 17th will be paid a $0.5786 dividend. This represents a yield of 254.0%. The ex-dividend date of this dividend is Monday, August 17th. Novo Nordisk A/S’s dividend payout ratio (DPR) is 42.79%.

Novo Nordisk A/S News Summary

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Oral Wegovy adoption is emerging as a potential catalyst. Jim Cramer highlighted accelerating pill prescriptions and argued that Wall Street’s initial negative reaction to Novo’s quarterly performance may have overlooked the company’s underlying strength. Jim Cramer Reevaluates Novo Nordisk as Wegovy Pill Adoption Accelerates
• Positive Sentiment: Unusually high call-option activity suggests some traders are positioning for a rebound: investors purchased roughly 100,752 calls, about 58% above typical volume. This is a market signal rather than a change in fundamentals.
• Positive Sentiment: Novo’s CEO Mike Doustdar said the obesity-drug market will not be dominated by a single company, arguing that patients will value differentiated treatments and that oral options could broaden demand. Novo CEO Says Obesity Market Won’t Be Winner-Take-All Battle With Lilly
• Neutral Sentiment: Zacks Research upgraded Novo Nordisk from “strong sell” to “hold,” indicating reduced bearishness but not a bullish recommendation. Erste Group also issued a fiscal-2026 earnings estimate, though no estimate details were provided.
• Negative Sentiment: Eli Lilly is gaining obesity-drug market share, creating concern that Lilly’s injectable and oral therapies could widen its competitive advantage even as Novo reports record prescriptions for oral Wegovy. Can Novo Nordisk’s GLP-1 Pill Momentum Offset Lilly’s Growing Edge?
• Negative Sentiment: The company’s chief executive acknowledged Lilly’s market-share gains, while an escalating marketing dispute highlights intensifying competition in the strategically important weight-loss market. Novo Nordisk Escalates Weight-Loss War With Eli Lilly

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.